Entero Therapeutics Reports Delisting Notice & Officer Changes
Ticker: GRDX · Form: 8-K · Filed: Mar 7, 2025 · CIK: 1604191
| Field | Detail |
|---|---|
| Company | Entero Therapeutics, Inc. (GRDX) |
| Form Type | 8-K |
| Filed Date | Mar 7, 2025 |
| Risk Level | high |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, management-change, agreement
TL;DR
Entero Therapeutics got a delisting warning and swapped some execs.
AI Summary
Entero Therapeutics, Inc. filed an 8-K on March 7, 2025, reporting several key events as of March 3, 2025. These include entering into a material definitive agreement, receiving a notice of delisting or failure to satisfy a continued listing rule, and changes in directors and officers, including compensatory arrangements. The filing also covers financial statements and exhibits.
Why It Matters
The company is facing potential delisting, which could significantly impact its stock liquidity and investor confidence, alongside changes in its leadership structure.
Risk Assessment
Risk Level: high — The notice of delisting or failure to satisfy a continued listing rule indicates significant financial or operational distress, posing a high risk to investors.
Key Players & Entities
- Entero Therapeutics, Inc. (company) — Filer of the 8-K report
- First Wave BioPharma, Inc. (company) — Former company name
- AzurRx BioPharma, Inc. (company) — Former company name
- BioPharma d'Azur, Inc. (company) — Former company name
FAQ
What is the specific material definitive agreement Entero Therapeutics entered into?
The filing indicates the entry into a material definitive agreement but does not specify its details within the provided text.
What is the reason for the notice of delisting or failure to satisfy a continued listing rule?
The provided text states there was a 'Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing' but does not detail the specific rule or standard not met.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing was on March 3, 2025.
What are the key items reported in this 8-K filing?
The key items reported are: Entry into a Material Definitive Agreement, Notice of Delisting or Failure to Satisfy a Continued Listing Rule, Departure/Election of Directors/Officers, and Financial Statements and Exhibits.
What was Entero Therapeutics, Inc. previously known as?
Entero Therapeutics, Inc. was formerly known as First Wave BioPharma, Inc., AzurRx BioPharma, Inc., and BioPharma d'Azur, Inc.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 7, 2025 regarding Entero Therapeutics, Inc. (GRDX).